Pharma Investment During COVID Crisis: The Sensex has weakened 2.93% so far in April but the Nifty Pharma Index has gained 9.2%.
Mutual Fund: Kovid-19 epidemic is spreading and the stock market is also worried about it. But last year, there has been evidence that the stock market has beaten as fast as it has recovered and has also recovered again. If new investors get an opportunity to enter the stock market, then those who put money on a company of good quality also made a profit. Technology, pharma and consumption-related stocks were at the forefront of profit-making – ie businesses for which the corona disaster also emerged as an opportunity. Pharma companies are working to increase the production of drugs and their Business is expected to continue to grow even further. If you do not want to take the risk of investing directly in shares, then you can place bets on this sector through mutual funds.
Mutual funds help you to start investing with less risk and also with less money. In the second wave of Corona, when the market is in turmoil, pharma stocks are showing strength. So far in April, the Sensex has weakened 2.93 per cent, but the pharma index has risen 9.2 per cent.
Pharma Funds made money
Most funds in the pharma sector have given returns of more than 50 percent. In this, if you look at the performance of DSP Healthcare Fund, you will see that it has earned 69.23 percent in a year. That is, if you had invested 1 lakh in it a year ago, it would have increased to Rs 1.69 lakh. On the other hand, if you had a SIP of Rs 10,000 every month, you would have deposited Rs 1.5 lakh. Similarly, ICICI Prudential Pharma Healthcare and Diagnostics Fund has also run 59.79 per cent in a year. Mirae Asset Healthcare, SBI Healthcare Opportunities Funj and Nippon India Pharma Fund have given returns between 56-58 per cent.
Where is the investment?
Pharma and healthcare funds invest in pharmaceutical companies or companies offering testing and diagnostic facilities. DSP talks about the healthcare fund. The fund has 8.67 per cent investment in Cipla, 7.68 per cent in Lupine and 6.86 per cent in Sun Pharma. The fund invests 6.81 per cent in Dr Reddy’s Lab and 6.77 per cent is in Ipca Lab.
Because these are equity funds, the risks are the same as in the equity market and experts recommend to maintain the investment for a long period for big profits.
